Tests modified immune cells in relapsed multiple myeloma and plasmacytoid lymphoma
Tests BCMA-CD19 CAR T cells, modified immune cells, in people with relapsed or refractory myeloma.
Plain-language title generated from the registry record
Registry title: BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
Key facts
- Where
- Chengdu and Shenzhen, ChinaSee the 2 sites
- Phase
- Phase 1
Where in China
- Chengdu Military General HospitalChengdu, ChinaTaking people
- Peking University Shenzhen Hospital, ChinaShenzhen, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- iCell Gene Therapeutics
- Trial code
- NCT04162353
- Record updated
- 16 September 2025
- Original description
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and/or refractory multiple myeloma and plasmacytoid lymphoma.Read full original descriptionShow less
BCMA-CD19 cCAR in Relapsed and /or Refractory Multiple Myeloma and Plasmacytoid Lymphoma
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and/or refractory multiple myeloma and plasmacytoid lymphoma.
Inclusion: Signed written informed consent; Patients volunteer to participate in the research; Diagnosis is mainly based on the World Health Organization (WHO) 2008; Patients have exhausted standard therapeutic options; Systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 1 weeks; Female must be not pregnant during the study.
Exclusion: Prior solid organ transplantation; Potentially curative therapy including chemotherapy or hematopoietic cell transplant; Prior treatment with BCMAxCD3 or CD19xCD3 bispecific agents; Patients declining to consent for treatment.